ArticleEmerging microbes & infections2026
Development and characterization of a recombinant Bundibugyo virus expressing a fluorescent reporter protein.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bundibugyo virus disease (BVD), caused by Bundibugyo virus (BDBV), is associated with substantial morbidity and mortality, with previous outbreaks reporting case fatality rates of 30%-50%. The ongoing BDBV outbreak in the Democratic Republic of the Congo and Uganda highlights the urgent need for virus-specific research tools and medical countermeasures. Unlike Ebola virus disease caused by Zaire ebolavirus, no licensed vaccines or specific therapeutics are currently available for BVD. The lack of research tools has limited studies with BDBV. To facilitate antiviral testing and neutralization studies, we developed the first recombinant BDBV expressing the fluorescent reporter protein ZsGreen (rBDBV-ZsG). As a proof of concept, we tested a set of previously characterized antiviral compounds and demonstrated comparable inhibitory profiles between rBDBV-ZsG and the wild-type BDBV parental strain. Furthermore, the utility of rBDBV-ZsG was successfully evaluated in neutralization assays, demonstrating robust sensitivity and specificity using monoclonal antibodies and convalescent serum samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.